Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRSN Mersana Therapeutics Inc.

Halted 01-06 08:52:51 EST

29.08

+0.04

+0.14%

High30.39	Low28.78	Vol710.46K
Open28.90	D1 Closing29.04	Amplitude5.54%
Mkt Cap145.36M	Tradable Cap109.15M	Total Shares5.00M
T/O20.77M	T/O Rate18.93%	Tradable Shares3.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MRSN","market":"US","secType":"STK","nameCN":"Mersana Therapeutics Inc.","latestPrice":29.08,"timestamp":1767646800000,"preClose":29.04,"halted":3,"volume":710460,"delay":0,"floatShares":3753400,"shares":4998750,"eps":-14.086146,"marketStatus":"Halted","change":0.04,"latestTime":"01-06 08:52:51 EST","open":28.9,"high":30.39,"low":28.78,"amount":20771706.23172,"amplitude":0.055441,"askPrice":31.1,"askSize":2,"bidPrice":29.25,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.086146,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767709800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1498622400000,"exchange":"NASDAQ","adjPreClose":29.08,"postHourTrading":{"tag":"盘后","latestPrice":29.3,"preClose":29.08,"latestTime":"19:36 EST","volume":116171,"amount":3381888.48,"timestamp":1767659781905},"volumeRatio":4.378290818102765,"impliedVol":0.2446,"impliedVolPercentile":0.2117},"requestUrl":"/m/hq/s/MRSN","defaultTab":"news","newsList":[{"id":"2601560278","title":"NASDAQ TRADE HALT  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2601560278","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601560278?lang=en_us&edition=fundamental","pubTime":"2026-01-06 08:50","pubTimestamp":1767660600,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nAQN2LGD3I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2590549013","title":"Serina Therapeutics Appoints Dr. Joshua Thomas as Vice President and Head of Chemistry","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549013","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549013?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:15","pubTimestamp":1765487710,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. has appointed Dr. Joshua Thomas as Vice President and Head of Chemistry. Dr. Thomas will oversee internal and external chemistry efforts to optimize POZ-based drug candidates, supporting the company's development pipeline. He previously held scientific leadership roles at Mersana Therapeutics and has expertise in discovery chemistry and antibody drug conjugate technologies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLb7spWt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","BK4139","IE00BKPKM429.USD","BK4588","LU2210150020.SGD","SER","BK4112","IE00B64PRP62.GBP","SG9999014013.SGD","MRSN","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014005.SGD","BK4563","LU0314104364.USD","LU2210149790.SGD","NDAQ","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2584922406","title":"Mersana Therapeutics Q3 EPS USD -1.51","url":"https://stock-news.laohu8.com/highlight/detail?id=2584922406","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584922406?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:47","pubTimestamp":1763574463,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - Mersana Therapeutics Q3 collaboration revenue USD 11.009 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 14-NOV-202511:59:00.077 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDc5ylrm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2583634640","title":"Mersana Therapeutics Faces High Stakes with Potential Day One Biopharmaceuticals Merger Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2583634640","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583634640?lang=en_us&edition=fundamental","pubTime":"2025-11-15 14:01","pubTimestamp":1763186460,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics (MRSN) has disclosed a new risk, in the Corporate Activity and Growth category. Mersana Therapeutics faces significant busines...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mersana-therapeutics-faces-high-stakes-with-potential-day-one-biopharmaceuticals-merger-delays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mersana-therapeutics-faces-high-stakes-with-potential-day-one-biopharmaceuticals-merger-delays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN","BK4139","BK4563","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2583892376","title":"BUZZ-Nasdaq biotech index hits record high, set to gain nearly 5% this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2583892376","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583892376?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:19","pubTimestamp":1763151555,"startTime":"0","endTime":"0","summary":"BUZZ-Nasdaq biotech index hits record high, set to gain nearly 5% this week** The Nasdaq biotechnology index .NBI touches a record high and is up 1.2% on Fri, putting the index on track for a roughly ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL6N3WQ0YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4563","MRSN","BK4505","DAWN","COGT","BK4139","BK4539","BK4007","ALKS"],"gpt_icon":0},{"id":"2583503683","title":"Mersana Therapeutics reports third quarter 2025 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503683","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583503683?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:09","pubTimestamp":1763122173,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc. reported a net loss of $7.5 million, or $1.51 per share, for the third quarter of 2025, compared to a net loss of $11.5 million, or $2.34 per share, in the same period of 2024. General and administrative expenses for the third quarter of 2025 were $6.3 million, down from $9.9 million in the third quarter of 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $56.4 million, compared to $134.6 million at December 31, 2024. The company announced it has entered into an agreement to be acquired by Day One Biopharmaceuticals Inc., with closing expected by the end of January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mersana Therapeutics Inc. published the original cont","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL6CStr9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","MRSN","DAWN","BK4563"],"gpt_icon":0},{"id":"2583087555","title":"BRIEF-Mersana Therapeutics Q3 EPS USD -1.51","url":"https://stock-news.laohu8.com/highlight/detail?id=2583087555","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583087555?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:00","pubTimestamp":1763121648,"startTime":"0","endTime":"0","summary":"BRIEF-Mersana Therapeutics Q3 EPS USD -1.51\n\n\nNov 14 (Reuters) - Mersana Therapeutics Q3 collaboration revenue USD 11.009 million.\n\nQ3 net income USD -7.545 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX9EE0FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","MRSN"],"gpt_icon":0},{"id":"2583508298","title":"Mersana Therapeutics Q3 Collaboration Revenue USD 11.009 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508298?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:00","pubTimestamp":1763121602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX9EE0FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRSN","BK4563","BK4139"],"gpt_icon":0},{"id":"2583714015","title":"U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66","url":"https://stock-news.laohu8.com/highlight/detail?id=2583714015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583714015?lang=en_us&edition=fundamental","pubTime":"2025-11-14 17:48","pubTimestamp":1763113706,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66Nov 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL4N3WQ0PY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SR","DRIO","SOC","WY","ANF","DINO","KOD","PBF","BK4505","LU0476273544.USD","PSX","EWTX","VLO","INO","DIS","BK4084","ENSG","IE00BGHQF417.EUR","KURA","LU1035775433.USD","SG9999014880.SGD","STUB","ACHC","FLY","IE00B5TLWC47.USD","MRSN","ARDT","LU0122379950.USD","CCAP","AMGN","DYN","EPC","IE0004445015.USD","APH","MPC","SBH","AMAT","GAP","CRS","LU2272731865.HKD","TDG","LU1153585028.USD","PLNT","ENTA","SG9999011175.SGD","LU0963586101.USD","PARR","DK","PGR"],"gpt_icon":1},{"id":"2583529845","title":"Mersana Therapeutics Inc : William Blair Cuts to Market Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583529845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583529845?lang=en_us&edition=fundamental","pubTime":"2025-11-14 13:55","pubTimestamp":1763099755,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WP1ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4139","MRSN"],"gpt_icon":0},{"id":"2583519718","title":"Sector Update: Health Care Stocks Edge Higher Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2583519718","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583519718?lang=en_us&edition=fundamental","pubTime":"2025-11-14 04:44","pubTimestamp":1763066682,"startTime":"0","endTime":"0","summary":"Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding less than 0.1%.The iShares Biotechnology ETF (IBB) de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BNTX","IE00B19Z3581.USD","LU0306806265.USD","LU0321505868.SGD","DAWN","LU0154236417.USD","LU0456855351.SGD","LU1023059063.AUD","IE00BKVL7J92.USD","LU0234572021.USD","LU0122379950.USD","LU0321505439.SGD","PFE","BK7095","MTSR","SG9999011175.SGD","SG9999013999.USD","IE0002270589.USD","LU0985481810.HKD","IE00BBT3K403.USD","BK4585","AKRO","BK4533","IE00B19Z3B42.SGD","BK4139","BK4539","LU0225771236.USD","LABU","LU0058720904.USD","BK7104","XLV","IE00BZ1G4Q59.USD","LU0306807586.USD","XBI","NVO.AU","LU0225284248.USD","BK4581","SG9999003800.SGD","SG9999001176.SGD","BK4563","LU1894683264.USD","IBB","BK4532","BK4599","MRSN","IE000M9KFDE8.USD","PFE.AU","BK4534","LU0868494617.USD"],"gpt_icon":1},{"id":"2583515095","title":"William Blair downgrades Mersana Therapeutics (MRSN) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2583515095","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583515095?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:15","pubTimestamp":1763061339,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics received a Hold rating and price target from William Blair analyst Andy Hsieh today. Hsieh covers the Healthcare sector, focus...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-downgrades-mersana-therapeutics-mrsn-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-downgrades-mersana-therapeutics-mrsn-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN"],"gpt_icon":0},{"id":"2583515940","title":"BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA","url":"https://stock-news.laohu8.com/highlight/detail?id=2583515940","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583515940?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:09","pubTimestamp":1763060958,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APAEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL6N3WP0NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APA","ARDT","IONS","SCVL","LU0234572021.USD","SG","AMAT","CLBT","CTEV","IE0009355771.USD","THAR","IMRX","MRK","SLB","EPC","BWEN","PSFE","KURA","SEE","MGRX","DDS","HL","SBH","NEM","CTRI","BTDR","SSYS","BR","HAL","ANNX","SPB","CDE","HZO","LU2458330243.SGD","VZ","MRSN","XNET","CVX","DASH","FLY","ALB"],"gpt_icon":1},{"id":"2583691592","title":"Mersana Therapeutics Inc : Baird Raises Target Price to $29 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2583691592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583691592?lang=en_us&edition=fundamental","pubTime":"2025-11-14 00:08","pubTimestamp":1763050136,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP23L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4139","MRSN"],"gpt_icon":0},{"id":"2583594068","title":"Mersana Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $29 From $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583594068?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:51","pubTimestamp":1763049077,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2583594577","title":"Mersana Therapeutics Inc : Truist Securities Cuts to Hold From Buy; Cuts Target Price to $30.75 From $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583594577?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:26","pubTimestamp":1763047603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2583591003","title":"Oppenheimer says Day One paying up to $285M for Mersana ‘is interesting’","url":"https://stock-news.laohu8.com/highlight/detail?id=2583591003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583591003?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:10","pubTimestamp":1763046624,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler notes Day One (DAWN) announced it was acquiring Mersana Therapeutics (MRSN) for its B7-H4 ADC being tested in a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-says-day-one-paying-up-to-285m-for-mersana-is-interesting-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-says-day-one-paying-up-to-285m-for-mersana-is-interesting-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4127","OPY","DAWN","MRSN","BK4139","BK4563"],"gpt_icon":0},{"id":"2583315591","title":"Mersana Therapeutics Inc : Btig Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2583315591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583315591?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:59","pubTimestamp":1763045980,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1SS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4139","MRSN"],"gpt_icon":0},{"id":"2583956058","title":"Mersana Therapeutics Inc : Wedbush Cuts Neutral From Outperform; Raises Target Price to $27.25 From $13","url":"https://stock-news.laohu8.com/highlight/detail?id=2583956058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583956058?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:50","pubTimestamp":1763038202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRSN","BK4139","BK4563"],"gpt_icon":0},{"id":"2583868561","title":"Day One to Buy Mersana Therapeutics for Up to $285 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583868561","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583868561?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:23","pubTimestamp":1763032980,"startTime":"0","endTime":"0","summary":"Day One Biopharmaceuticals has struck a deal to buy fellow biopharmaceutical company Mersana Therapeutics for up to $285 million in cash.Day One on Thursday said it will pay an initial $25 a share, or $119 million, for Mersana, nearly triple Wednesday's closing price of $8.87 for the Cambridge, Mass., clinical-stage company.Mersana shareholders will also receive contingent value rights worth up to an additional $30.25 a share, for a total potential deal consideration of $55.25 a share.Shares of Mersana were recently up 215% at $27.95 in premarket trading.Day One, based in Brisbane, Calif., said the acquisition of Mersana bolsters its portfolio with the antibody-drug conjugate emiltatug ledadotin, which has shown early anti-tumor activity in a Phase 1 study in adenoid cystic carcinoma type-1, a cancer with high unmet need and a lack of therapeutic options.The contingent value rights in the deal are tied to development and sales milestones for emiltatug ledadotin.Day One said it plans us","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","DAWN","BK4563","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mersana.com","stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.047},{"period":"3month","weight":2.6533},{"period":"6month","weight":2.4496},{"period":"1year","weight":-0.1632},{"period":"ytd","weight":0.0052}],"compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.003},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.102},{"period":"1year","weight":0.1618},{"period":"ytd","weight":0.0085}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.048116},{"month":2,"riseRate":0.5,"avgChangeRate":0.134625},{"month":3,"riseRate":0,"avgChangeRate":-0.187861},{"month":4,"riseRate":0.5,"avgChangeRate":0.056403},{"month":5,"riseRate":0.375,"avgChangeRate":0.215196},{"month":6,"riseRate":0.25,"avgChangeRate":-0.085605},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.150945},{"month":8,"riseRate":0.555556,"avgChangeRate":0.059378},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.078098},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.008583},{"month":11,"riseRate":0.666667,"avgChangeRate":0.402507},{"month":12,"riseRate":0.444444,"avgChangeRate":0.006431}],"exchange":"NASDAQ","name":"Mersana Therapeutics Inc.","nameEN":"Mersana Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mersana Therapeutics Inc.,MRSN,Mersana Therapeutics Inc.股票,Mersana Therapeutics Inc.股票老虎,Mersana Therapeutics Inc.股票老虎国际,Mersana Therapeutics Inc.行情,Mersana Therapeutics Inc.股票行情,Mersana Therapeutics Inc.股价,Mersana Therapeutics Inc.股市,Mersana Therapeutics Inc.股票价格,Mersana Therapeutics Inc.股票交易,Mersana Therapeutics Inc.股票购买,Mersana Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}